Option Care Health, Inc. (NASDAQ:OPCH) Forecasted to Earn FY2024 Earnings of $1.15 Per Share

Option Care Health, Inc. (NASDAQ:OPCH) – Research analysts at Barrington Research upped their FY2024 earnings per share (EPS) estimates for shares of Option Care Health in a note issued to investors on Wednesday, April 24th. Barrington Research analyst M. Petusky now forecasts that the company will post earnings per share of $1.15 for the year, up from their prior forecast of $1.10. Barrington Research has a “Outperform” rating and a $38.00 price objective on the stock. The consensus estimate for Option Care Health’s current full-year earnings is $1.18 per share. Barrington Research also issued estimates for Option Care Health’s FY2025 earnings at $1.35 EPS.

Separately, Jefferies Financial Group lifted their target price on Option Care Health from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, March 4th.

Option Care Health Price Performance

Shares of OPCH opened at $29.61 on Friday. The firm has a market cap of $5.15 billion, a price-to-earnings ratio of 19.48, a PEG ratio of 1.43 and a beta of 1.22. The stock has a 50 day moving average of $31.96 and a 200-day moving average of $31.48. The company has a current ratio of 1.77, a quick ratio of 1.33 and a debt-to-equity ratio of 0.74. Option Care Health has a 52 week low of $24.23 and a 52 week high of $35.74.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings data on Tuesday, April 23rd. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. Option Care Health had a return on equity of 18.92% and a net margin of 6.15%. The firm had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter last year, the firm earned $0.21 EPS. Option Care Health’s quarterly revenue was up 12.8% on a year-over-year basis.

Insider Transactions at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. purchased 35,000 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were acquired at an average price of $31.55 per share, with a total value of $1,104,250.00. Following the acquisition, the director now owns 269,528 shares in the company, valued at approximately $8,503,608.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.64% of the company’s stock.

Institutional Trading of Option Care Health

Hedge funds have recently made changes to their positions in the stock. Mutual of America Capital Management LLC raised its stake in shares of Option Care Health by 63.3% in the 4th quarter. Mutual of America Capital Management LLC now owns 190,684 shares of the company’s stock worth $6,424,000 after buying an additional 73,938 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Option Care Health by 15.9% in the third quarter. Wellington Management Group LLP now owns 2,896,392 shares of the company’s stock worth $93,698,000 after buying an additional 397,627 shares during the last quarter. HealthInvest Partners AB acquired a new stake in shares of Option Care Health in the fourth quarter worth about $1,254,000. Ontario Teachers Pension Plan Board acquired a new position in shares of Option Care Health during the 3rd quarter worth about $546,000. Finally, Van ECK Associates Corp lifted its position in shares of Option Care Health by 244.2% during the 3rd quarter. Van ECK Associates Corp now owns 34,291 shares of the company’s stock worth $1,109,000 after purchasing an additional 24,328 shares during the last quarter. Institutional investors own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.